Synthesis and Biological Evaluation of Bivalent Ligands for the Cannabinoid 1 Receptor
- 16 September 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (19) , 7048-7060
Abstract
Dimerization or oligomerization of many G-protein-coupled receptors (GPCRs), including the cannabinoid 1 (CB1) receptor, is now widely accepted and may have significant implications for medications development targeting these receptor complexes. A library of bivalent ligands composed of two identical CB1 antagonist pharmacophores derived from SR141716 linked by spacers of various lengths were developed. The affinities of these bivalent ligands at CB1 and CB2 receptors were determined using radiolabeled binding assays. Their functional activities were measured using GTP-γ-S accumulation and intracellular calcium mobilization assays. The results suggest that the nature of the linker and its length are crucial factors for optimum interactions of these ligands at CB1 receptor binding sites. Finally, selected bivalent ligands (5d and 7b) were able to attenuate the antinociceptive effects of the cannabinoid agonist CP55,940 (21) in a rodent tail-flick assay. These novel compounds may serve as probes that will enable further characterization of CB1 receptor dimerization and oligomerization and its functional significance and may prove useful in the development of new therapeutic approaches to G-protein-coupled receptor mediated disorders.Keywords
This publication has 55 references indexed in Scilit:
- Synthesis and evaluation of homodimeric GnRHR antagonists having a rigid bis-propargylated benzene coreBioorganic & Medicinal Chemistry, 2008
- G‐protein‐coupled receptor heteromers: function and ligand pharmacologyBritish Journal of Pharmacology, 2008
- The synthesis of bivalent 2β-carbomethoxy-3β-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transportersBioorganic & Medicinal Chemistry, 2008
- Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic EffectsMolecular Pharmacology, 2007
- Heterodimerization and surface localization of G protein coupled receptorsBiochemical Pharmacology, 2007
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- New Opioid Designed Multiple Ligand from Dmt-Tic and Morphinan PharmacophoresJournal of Medicinal Chemistry, 2006
- Cannabinoid receptor homo- and heterodimerizationLife Sciences, 2005
- A Bivalent Ligand (KDAN-18) Containing δ-Antagonist and κ-Agonist Pharmacophores Bridges δ2 and κ1 Opioid Receptor PhenotypesJournal of Medicinal Chemistry, 2004
- A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ HeterodimersJournal of Medicinal Chemistry, 2004